Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the SAMURAI Clinical Study is to collect data to confirm the safety, performance and effectiveness of the ImageReady System for use in the Magnetic Resonance Imaging (MRI) environment when used in accordance with the Conditions of Use included in the Boston Scientific MRI Technical Guide
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MRI Group | Experimental | Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant. |
|
| Control Group | Experimental | Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MRI | Radiation | The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Without MR Scan-related Complications | The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit. | MRI Visit + 1 Month |
| Success Rate for Threshold Measurement at 1 Month Post-MRI Scan or Control Group Visit | The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up. Subjects with an increase in pacing thresholds s 0.5V (at 0.5 ms) from pre-MR Scan/Control Group visit to MRI/Control visit + 1 Month follow-up were considered a success. A success rate was calculated for both the MRI and the Control Groups. | MRI + 1 Month Visit |
| Success Rate for Sensed Amplitude Measurement at 1 Month Post-MRI Scan or Control Group Visit | The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up. Data were analyzed separately by chamber, Right Atrium (RA) and Right Ventricle (RV), for this endpoint. | MRI + 1 Month Visit |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Without ImageReady System-related Complications | Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for all subjects who underwent an implant procedure and and reached 91 days of follow-up. | 3 months post implant |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject has or has had any pacing or ICD system implants
Subject has any MR Unsafe implants or devices with an unknown MR status, including MR Unsafe sternal wires, neurostimulators, biostimulator, metals or alloys, per labeling of each implant
Subject has any MR Conditional implants or devices that impact the ability to conduct this protocol
Subject needs or will need another MR scan within 14 weeks of system implant, other than that required by the SAMURAI Study
Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)
Subject has a mechanical tricuspid heart valve
Subject is enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries* that are not in conflict and do not affect the following:
Subjects with documented permanent or persistent AF where the physician intends to implant a dual chamber pulse generator (single chamber VVIR pulse generators are acceptable)
Subject is currently on the active heart transplant list
Subject has documented life expectancy of less than 12 months
Women of childbearing potential who are or might be pregnant at the time of study enrollment or ImageReady MR Conditional Pacing System implant (method of assessment upon physician's discretion)
Subjects currently requiring dialysis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ronald Berger, MD, PhD | Johns Hopkins Hospital, Carnegie 530, 600 N. Wolfe St, Baltimore, MD 21287 | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Banner Heart Hospital | Mesa | Arizona | 85206 | United States | ||
| USC Medical Center |
Not provided
363 patients were consented and enrolled in this study. 11 patients were withdrawn pre-implantation. 352 patients underwent the implantation procedure and 348 patients were successfully implanted. 1 patient died prior to randomization.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | MRI Group | Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant. MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment ImageReady System implant: Pacemaker and lead(s) implant |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ImageReady System implant | Device | Pacemaker and lead(s) implant |
|
|
| Los Angeles |
| California |
| 90033 |
| United States |
| University of California, San Francisco | San Francisco | California | 94143 | United States |
| Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | United States |
| Orlando Regional Medical Center | Orlando | Florida | 32806 | United States |
| University Community Hospital | Trinity | Florida | 34655 | United States |
| Emory University Hospital | Atlanta | Georgia | 30322 | United States |
| University of Chicago Hospital | Chicago | Illinois | 60637 | United States |
| Alexian Brothers Medical Center | Elk Grove Village | Illinois | 60007 | United States |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | United States |
| William Beaumont Hospital | Royal Oak | Michigan | 48098 | United States |
| St Mary's Duluth Clinic Regional Heart Center | Duluth | Minnesota | 55805 | United States |
| United Heart and Vascular Clinic | Saint Paul | Minnesota | 55102 | United States |
| Billings Clinic | Billings | Montana | 59101 | United States |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | United States |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | United States |
| OhioHealth Research and Innovation Institute | Columbus | Ohio | 43214 | United States |
| Trinity West Hospital | Steubenville | Ohio | 43952 | United States |
| Abington Memorial Hospital | Philadelphia | Pennsylvania | 19001 | United States |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | United States |
| Avera Heart Hospital of South Dakota | Sioux Falls | South Dakota | 57108 | United States |
| Texas Cardiac Arrhythmia Research Foundation | Austin | Texas | 78705 | United States |
| Medical City Dallas Hospital | Dallas | Texas | 75230 | United States |
| Trinity Mother Health Systems | Tyler | Texas | 75701 | United States |
| Martha Jefferson Hospital | Charlottesville | Virginia | 22911 | United States |
| Sentara Norfolk General Hospital | Norfolk | Virginia | 23507 | United States |
| Virginia Commonwealth University Health System | Richmond | Virginia | 23219 | United States |
| University of Washington Medical Center | Seattle | Washington | 98195 | United States |
| Froedtert Memorial Lutheran Hospital - Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |
| St Vincent's Hospital | Melbourne | Victoria | Australia |
| Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Ste Foy | Quebec | Canada |
| Queen Mary Hospital | Hong Kong | Hong Kong | 00000 | China |
| Hillel Yaffe Medical Center | Hadera | Israel |
| Rambam Medical Center | Haifa | 31096 | Israel |
| The Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
| Sheba Medical Center | Tel Litwinsky | Israel |
| Institut Jantung Negara | Kuala Lumpur | 50400 | Malaysia |
| University Malaya Medical Center | Kuala Lumpur | 50603 | Malaysia |
| National Heart Centre | Singapore | 168752 | Singapore |
| National University Hospital, Singapore | Singapore | Singapore |
| Tan Tock Seng Hospital | Singapore | Singapore |
| Control Group |
Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups. ImageReady System implant: Pacemaker and lead(s) implant |
| FG002 | Patients Withdrawn Prior to Randomization | Patients who consented to the study but were withdrawn prior to the randomization. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | MRI Group | Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant. MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment ImageReady System implant: Pacemaker and lead(s) implant |
| BG001 | Control Group | Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups. ImageReady System implant: Pacemaker and lead(s) implant |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Participants Without MR Scan-related Complications | The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit. | The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who underwent any portion of the MRI scan sequences and did not have a medically necessary scan performed prior to the MRI visit + 1 month follow-up. | Posted | Number | 95% Confidence Interval | Percentage of participants | MRI Visit + 1 Month |
|
|
| |||||||||||||||||||||||||
| Primary | Success Rate for Threshold Measurement at 1 Month Post-MRI Scan or Control Group Visit | The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up. Subjects with an increase in pacing thresholds s 0.5V (at 0.5 ms) from pre-MR Scan/Control Group visit to MRI/Control visit + 1 Month follow-up were considered a success. A success rate was calculated for both the MRI and the Control Groups. | For the per-protocol analysis, a total of 96 Control Group subjects and 167 MRI Group subjects had paired threshold measurements and met the inclusion criteria. | Posted | Number | % of participants with success | MRI + 1 Month Visit |
| ||||||||||||||||||||||||||||
| Primary | Success Rate for Sensed Amplitude Measurement at 1 Month Post-MRI Scan or Control Group Visit | The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up. Data were analyzed separately by chamber, Right Atrium (RA) and Right Ventricle (RV), for this endpoint. | Right Atrium: a total of 78 Control Group subjects and 135 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria. Right Ventricle: a total of 91 Control Group subjects and 152 MRI Group subjects had paired sensed amplitude measurements and met the inclusion criteria. | Posted | Number | % of participants with success | MRI + 1 Month Visit |
| ||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Without ImageReady System-related Complications | Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for all subjects who underwent an implant procedure and and reached 91 days of follow-up. | Posted | Number | 95% Confidence Interval | Percentage of participants | 3 months post implant |
|
|
Adverse events are collected from enrollment through whole course of the study. Long-term follow-up is ongoing; subjects enrolled in SAMURAI study will be followed for 5 years post-implant.
All Adverse Events are collected, as per ISO 14155: 2011 and/or 21 CFR Part 812.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | MRI Group | Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant. MRI: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment ImageReady System implant: Pacemaker and lead(s) implant | 123 | 229 | 163 | 229 | ||
| EG001 | Control Group | Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups. ImageReady System implant: Pacemaker and lead(s) implant | 67 | 118 | 82 | 118 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Early ERI - Random component failure | Product Issues | Non-systematic Assessment |
| ||
| Erosion | Product Issues | Non-systematic Assessment |
| ||
| Infection (> 30 days post-implant) | Product Issues | Non-systematic Assessment |
| ||
| Impedance > 2000 ohms - RA | Product Issues | Non-systematic Assessment |
| ||
| Dislodgment - RA | Product Issues | Non-systematic Assessment |
| ||
| Other - RA Lead | Product Issues | Non-systematic Assessment |
| ||
| Elevated threshold - RV | Product Issues | Non-systematic Assessment |
| ||
| Myocardial perforation post-implant - RV | Product Issues | Non-systematic Assessment |
| ||
| Impedance > 2000 ohms - RV | Product Issues | Non-systematic Assessment |
| ||
| Dislodgment - RV | Product Issues | Non-systematic Assessment |
| ||
| Post-surgical infection (<= 30 days post-implant) | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Adverse reaction - General | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Physical trauma | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Myocardial perforation without tamponade | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Myocardial perforation with tamponade | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Venous occlusion | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Adverse reaction - General | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Dyspnea - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Pulmonary edema - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Fatigue - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Heart failure symptoms - Unspecified | Cardiac disorders | Non-systematic Assessment |
| ||
| Multiple heart failure symptoms | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypertension - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Heart failure patient condition | Cardiac disorders | Non-systematic Assessment |
| ||
| 3rd degree AV block | Cardiac disorders | Non-systematic Assessment |
| ||
| Ventricular fibrillation (VF) | Cardiac disorders | Non-systematic Assessment |
| ||
| Ventricular tachycardia (VT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Torsades des pointes | Cardiac disorders | Non-systematic Assessment |
| ||
| Nonsustained ventricular tachycardia (NSVT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Atrial fibrillation (AF) | Cardiac disorders | Non-systematic Assessment |
| ||
| Atrial flutter | Cardiac disorders | Non-systematic Assessment |
| ||
| Other SVT (AVRT, AVNRT, EAT etc.) | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypotension | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypertension | Cardiac disorders | Non-systematic Assessment |
| ||
| Cardiac arrest | Cardiac disorders | Non-systematic Assessment |
| ||
| Myocardial infarction | Cardiac disorders | Non-systematic Assessment |
| ||
| Peripheral vascular disease | Cardiac disorders | Non-systematic Assessment |
| ||
| Aortic stenosis | Cardiac disorders | Non-systematic Assessment |
| ||
| Mitral regurgitation | Cardiac disorders | Non-systematic Assessment |
| ||
| Syncope | Cardiac disorders | Non-systematic Assessment |
| ||
| Dizziness | Cardiac disorders | Non-systematic Assessment |
| ||
| Chest pain - Ischemic | Cardiac disorders | Non-systematic Assessment |
| ||
| Chest pain - Other | Cardiac disorders | Non-systematic Assessment |
| ||
| Dyspnea | Cardiac disorders | Non-systematic Assessment |
| ||
| Palpitations | Cardiac disorders | Non-systematic Assessment |
| ||
| Multiple symptoms | Cardiac disorders | Non-systematic Assessment |
| ||
| Transient ischemic attack (TIA) | Cardiac disorders | Non-systematic Assessment |
| ||
| Cerebrovascular accident (CVA) | Cardiac disorders | Non-systematic Assessment |
| ||
| Deep vein thrombosis (DVT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Pulmonary embolism (PE) | Cardiac disorders | Non-systematic Assessment |
| ||
| Intracardiac thrombus | Cardiac disorders | Non-systematic Assessment |
| ||
| Hemorrhage | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Patient condition | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Patient condition | General disorders | Non-systematic Assessment |
| ||
| Death | General disorders | Non-systematic Assessment |
| ||
| Systemic infection | Infections and infestations | Non-systematic Assessment |
| ||
| Fever | Infections and infestations | Non-systematic Assessment |
| ||
| Physical trauma | General disorders | Non-systematic Assessment |
| ||
| Abnormal laboratory values | General disorders | Non-systematic Assessment |
| ||
| Hematological | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Neurological | Nervous system disorders | Non-systematic Assessment |
| ||
| Gastrointestinal | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Pulmonary | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Genitourinary | Reproductive system and breast disorders | Non-systematic Assessment |
| ||
| Renal | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Musculoskeletal | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Psychological | Psychiatric disorders | Non-systematic Assessment |
| ||
| Integumentary | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Head, eyes, ears, nose, throat (HEENT) | General disorders | Non-systematic Assessment |
| ||
| Endocrine | Endocrine disorders | Non-systematic Assessment |
| ||
| Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| Multi-system failure | General disorders | Non-systematic Assessment |
| ||
| AV Block Intermittent | Cardiac disorders | Non-systematic Assessment |
| ||
| Adverse Reaction - Allergic | General disorders | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oversensing - RA | Product Issues | Non-systematic Assessment |
| ||
| Undersensing - RA | Product Issues | Non-systematic Assessment |
| ||
| Other - PG system | Product Issues | Non-systematic Assessment |
| ||
| Oversensing - RV | Product Issues | Non-systematic Assessment |
| ||
| Rate response inappropriate | Product Issues | Non-systematic Assessment |
| ||
| Inappropriate AV delay | Product Issues | Non-systematic Assessment |
| ||
| Pacemaker-mediated tachycardia (PMT) | Product Issues | Non-systematic Assessment |
| ||
| Hematoma - Pocket (> 30 days post-implant) | Product Issues | Non-systematic Assessment |
| ||
| Oversensing - RA | Product Issues | Non-systematic Assessment |
| ||
| Undersensing - RA | Product Issues | Non-systematic Assessment |
| ||
| Extracardiac stimulation - RA | Product Issues | Non-systematic Assessment |
| ||
| Dislodgment - RA | Product Issues | Non-systematic Assessment |
| ||
| Other - RA Lead | Product Issues | Non-systematic Assessment |
| ||
| Oversensing - RV | Product Issues | Non-systematic Assessment |
| ||
| Undersensing - RV | Product Issues | Non-systematic Assessment |
| ||
| Elevated threshold - RV | Product Issues | Non-systematic Assessment |
| ||
| Extracardiac stimulation - RV | Product Issues | Non-systematic Assessment |
| ||
| Post-surgical wound discomfort | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Post-surgical pocket hemorrhage | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Post-surgical infection (<= 30 days post-implant) | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Chest pain | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Hematoma - Pocket (<=30 days post-implant) | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Puncture site hematoma - Procedure | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Pneumothorax - Procedure | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Myocardial perforation without tamponade | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Venous occlusion | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Other - PG system procedure | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Protocol Testing - Adverse reaction - General | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Other - Protocol Testing | Surgical and medical procedures | Non-systematic Assessment |
| ||
| Dyspnea - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Peripheral edema - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Pulmonary edema - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypotension - Heart failure | Cardiac disorders | Non-systematic Assessment |
| ||
| Heart failure symptoms - Unspecified | Cardiac disorders | Non-systematic Assessment |
| ||
| Multiple heart failure symptoms | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Heart failure patient condition | Cardiac disorders | Non-systematic Assessment |
| ||
| Sinus bradycardia | Cardiac disorders | Non-systematic Assessment |
| ||
| Chronotropic incompetence | Cardiac disorders | Non-systematic Assessment |
| ||
| Ventricular tachycardia (VT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Nonsustained ventricular tachycardia (NSVT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Atrial fibrillation (AF) | Cardiac disorders | Non-systematic Assessment |
| ||
| Atrial flutter | Cardiac disorders | Non-systematic Assessment |
| ||
| Sinus tachycardia | Cardiac disorders | Non-systematic Assessment |
| ||
| Other SVT (AVRT, AVNRT, EAT etc.) | Cardiac disorders | Non-systematic Assessment |
| ||
| Premature ventricular contractions (PVC) | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypotension | Cardiac disorders | Non-systematic Assessment |
| ||
| Hypertension | Cardiac disorders | Non-systematic Assessment |
| ||
| Peripheral vascular disease | Cardiac disorders | Non-systematic Assessment |
| ||
| Aortic stenosis | Cardiac disorders | Non-systematic Assessment |
| ||
| Mitral regurgitation | Cardiac disorders | Non-systematic Assessment |
| ||
| Syncope | Cardiac disorders | Non-systematic Assessment |
| ||
| Dizziness | Cardiac disorders | Non-systematic Assessment |
| ||
| Chest pain - Ischemic | Cardiac disorders | Non-systematic Assessment |
| ||
| Chest pain - Other | Cardiac disorders | Non-systematic Assessment |
| ||
| Dyspnea | Cardiac disorders | Non-systematic Assessment |
| ||
| Palpitations | Cardiac disorders | Non-systematic Assessment |
| ||
| Fatigue | Cardiac disorders | Non-systematic Assessment |
| ||
| Multiple symptoms | Cardiac disorders | Non-systematic Assessment |
| ||
| Cerebrovascular accident (CVA) | Cardiac disorders | Non-systematic Assessment |
| ||
| Deep vein thrombosis (DVT) | Cardiac disorders | Non-systematic Assessment |
| ||
| Distal thromboemboli | Cardiac disorders | Non-systematic Assessment |
| ||
| Pericardial effusion - Unrelated to procedure | Cardiac disorders | Non-systematic Assessment |
| ||
| Hematoma - Unrelated to procedure or device | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Patient condition | Cardiac disorders | Non-systematic Assessment |
| ||
| Other - Patient condition | General disorders | Non-systematic Assessment |
| ||
| Systemic infection | Infections and infestations | Non-systematic Assessment |
| ||
| Physical trauma | General disorders | Non-systematic Assessment |
| ||
| Abnormal laboratory values | General disorders | Non-systematic Assessment |
| ||
| Hematological | Blood and lymphatic system disorders | Non-systematic Assessment |
| ||
| Neurological | Nervous system disorders | Non-systematic Assessment |
| ||
| Gastrointestinal | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Pulmonary | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Genitourinary | Reproductive system and breast disorders | Non-systematic Assessment |
| ||
| Renal | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Musculoskeletal | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| Psychological | Psychiatric disorders | Non-systematic Assessment |
| ||
| Integumentary | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Head, eyes, ears, nose, throat (HEENT) | General disorders | Non-systematic Assessment |
| ||
| Endocrine | Endocrine disorders | Non-systematic Assessment |
| ||
| Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| AV Block Intermittent | Cardiac disorders | Non-systematic Assessment |
| ||
| Extracardiac stimulation - LV | Product Issues | Non-systematic Assessment |
| ||
| Adverse Reaction - Allergic | General disorders | Non-systematic Assessment |
|
The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kelly Aspinwall | Boston Scientific | 651-582-4560 | Kelly.Aspinwall@bsci.com |
| ID | Term |
|---|---|
| D001919 | Bradycardia |
| D012804 | Sick Sinus Syndrome |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001146 | Arrhythmia, Sinus |
| D006327 | Heart Block |
| D000075224 | Cardiac Conduction System Disease |
Not provided
Not provided
| Male |
|
| Singapore |
|
| United States |
|
| China |
|
| Malaysia |
|
| Israel |
|
| Australia |
|
|
|
|
|
|
|
|